NASDAQ | DRNA

$4.52 + 0.04 (+0.893%)

3 month stock price graph

4:00 PM ET on Sep 21, 2017 Pricing delayed 20 minutes

Investors & Media

Press Releases

 
Press Releases
  Date Title and Summary View
May 9, 2016
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported financial and operational results for the first quarter ended ...
May 2, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2016 financial results after market close on Monday, May 9, 2016. ...
Apr 18, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced the appointment of John B. "Jack" Green as chief financial officer (CFO), effective immediately. Mr. Green has served as the Company's ...
Mar 10, 2016
-Management to Host Conference Call Today at 4:30 pm ET- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced financial and operational results for the quarter a...
Mar 4, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference therapeutics, announced that the Company will release its fourth quarter and full year 2015 financial results after market close on Thursday, March 10, 2016. ...
Mar 2, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the following conferences: ...
Feb 25, 2016
Data from Asia TIDES Presentation Suggest Feasibility of Proprietary Approach for Delivery of RNAi-based Therapy to the Liver via Subcutaneous or Intravenous Injection CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of ...
Feb 4, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Leerink Partners 5th Annual Global Healthcar...
Dec 31, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based therapeutics targeting rare inherited diseases involving the liver and for cancers that are genetically defined, today announced that on December 31, 2015, the Compensat...
Dec 21, 2015
- Company Expects to Initiate Phase 1 Trial in Patients with PH1 in Early 2016 - - Ongoing Observational Study Measures Biomarkers Implicated in the Pathogenesis of PH1 - - Company Identifies DsiRNA-EX-Conjugate Clinical Candidates Targeting HAO1 Gene for Subcutaneous (SC)...
Page: FirstPrevious
4
... NextLast
= add release to Briefcase